Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 vs conventional care prior to allo-HCT in higher-risk MDS and oligoblastic AML
2018-002430-21Phase 2Active
- Sponsor
- GWT-TUD
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cytarabine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by GWT-TUD. Primary endpoint: 2-year event-free survival. Started Mar 2019; status: active.
02
Drugs
cytarabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-002430-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002430-21.